Super-Treg: Toward a New Era of Adoptive Treg Therapy Enabled by Genetic Modifications - Archive ouverte HAL Access content directly
Journal Articles Frontiers in Immunology Year : 2021

Super-Treg: Toward a New Era of Adoptive Treg Therapy Enabled by Genetic Modifications

Abstract

Regulatory Tcells (Treg) are essential components of peripheral immune homeostasis. Adoptive Treg cell therapy has shown efficacy in a variety of immune-mediated diseases in preclinical studies and is now moving from phase I/IIa to larger phase II studies aiming to demonstrate efficacy. However, hurdles such as in vivo stability and efficacy remain to be addressed. Nevertheless, preclinical models have shown that Treg function and specificity can be increased by pharmacological substances or gene modifications, and even that conventional T cells can be converted to Treg potentially providing new sources of Treg and facilitating Treg cell therapy. The exponential growth in genetic engineering techniques and their application to T cells coupled to a large body of knowledge on Treg open numerous opportunities to generate Treg with “superpowers”. This review summarizes the genetic engineering techniques available and their applications for the next-generation of Super-Treg with increased function, stability, redirected specificity and survival.
Fichier principal
Vignette du fichier
fimmu-11-611638.pdf (2.72 Mo) Télécharger le fichier
Origin Publication funded by an institution
Licence

Dates and versions

hal-03450503 , version 1 (22-05-2024)

Licence

Identifiers

Cite

Leila Amini, Jenny Greig, Michael Schmueck-Henneresse, Hans-Dieter Volk, Séverine Bézie, et al.. Super-Treg: Toward a New Era of Adoptive Treg Therapy Enabled by Genetic Modifications. Frontiers in Immunology, 2021, 11, ⟨10.3389/fimmu.2020.611638⟩. ⟨hal-03450503⟩
14 View
0 Download

Altmetric

Share

Gmail Mastodon Facebook X LinkedIn More